Shareholder plans sale of 150,000 common shares

A shareholder in DNLI has filed a notice of intent to sell 150,000 shares of common stock on the NASDAQ, with an aggregate market value of $3,324,060.

Rhea-AI Filing Summary

A shareholder in DNLI has filed a notice of intent to sell 150,000 shares of common stock on the NASDAQ, with an aggregate market value of $3,324,060. The planned sales are to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of February 3, 2026.

The shares were acquired on February 2, 2026 by exercising stock options under a registered plan, in three transactions for 22,042, 44,021, and 83,937 shares, all paid in cash. The filing notes that there were 146,661,833 shares of this class of stock outstanding.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for DNLI disclose?

The Form 144 shows a DNLI shareholder intends to sell 150,000 common shares on NASDAQ, valued at about $3,324,060. The shares were recently acquired by exercising stock options under a registered plan and will be sold through Morgan Stanley Smith Barney.

How many DNLI shares are planned to be sold under this Form 144?

The filing indicates a proposed sale of 150,000 DNLI common shares. These shares were obtained via recent stock option exercises and are planned for sale on the NASDAQ through Morgan Stanley Smith Barney, subject to Rule 144 resale conditions and market execution.

What is the aggregate market value of DNLI shares in this Form 144?

The proposed DNLI share sale has an indicated aggregate market value of about $3,324,060. This value is based on 150,000 common shares listed in the filing and reflects the approximate market pricing at the time the notice was prepared.

When were the DNLI shares in the Form 144 acquired and how?

The DNLI shares were acquired on February 2, 2026 through exercise of options under a registered plan. Three option exercises totaling 150,000 shares were completed, and the form specifies that payment for these exercises was made entirely in cash.

On which exchange will the DNLI Form 144 shares be sold?

The Form 144 states that the 150,000 DNLI common shares are intended to be sold on the NASDAQ stock market. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker handling the planned transaction for the shareholder.

How many DNLI shares are outstanding according to the Form 144?

The filing reports that there are 146,661,833 DNLI common shares outstanding. This figure provides context for the planned sale of 150,000 shares, indicating the relative size of the proposed transaction compared with the total shares currently in circulation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:47 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001724605
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DENALI THERAPEUTICS INC.
SEC File Number	001-38311
Address of Issuer	161 Oyster Point Blvd South San Francisco CALIFORNIA 94080
Phone	(650) 866-8547
Name of Person for Whose Account the Securities are To Be Sold	CAROLE HO
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	150000	3324060.00	146661833	02/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/02/2026	Exercise of options under a registered plan	Issuer			22042	02/02/2026	Cash
Common	02/02/2026	Exercise of options under a registered plan	Issuer			44021	02/02/2026	Cash
Common	02/02/2026	Exercise of options under a registered plan	Issuer			83937	02/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Carole Ho
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)